All News

Germany Post AMNOG

Pharmaceutical Executive

While emerging markets continue to represent a new channel of demand for pharmaceutical products, manufacturers have quickly realized that significant attention must still be given to more established markets, such as Germany.

Pharmaceutical Executive

The growing insistence on making healthcare more patient-centered - Europe is currently awash with declarations of intent along those lines - is generating a new level of interest in helping patients (or even citizens) to meet the expectations that the new orthodoxy is creating.

mosquito.png

Pharmaceutical Executive

The Cleveland Clinic once again ended its Medical Innovation Summit with a list of 10 advances voted most likely to have a major impact on improving patient care in 2015.

Pharmaceutical Executive

Israel’s pharmaceutical market value will increase from approximately $1.9 billion in 2013 to $2.34 billion, a compound annual growth rate of 2.8%, by 2020, says UK research and consulting firm GlobalData.

Pharmaceutical Executive

We hear it all the time these days: research processes have to undergo transformative changes in order for research organizations to thrive-or even survive. Controlled clinical trials take too long and cost too much. Regulatory review is blocking innovation.

Pharmaceutical Executive

A federal policy issued late last week appeared to deal a serious blow to continuing medical education (CME) programs supported by biopharma companies. But the specifics published by the Centers for Medicare and Medicaid Services (CMS) Oct. 31, 2014 actually continue to exempt independent CME funding from the Open Payments reporting requirements for transfers of value from manufacturers to prescribers.

Pharmaceutical Executive

Christopher A. Viehbacher resigned as director of Sanofi immediately after its Board of Directors unanimously agreed to remove him as the company’s CEO yesterday. Chairman Serge Weinberg will replace Viehbacher on an interim basis.

Pharmaceutical Executive

After having already sequenced thousands of cancer genes in projects together, the Yale School of Medicine and Gilead announced they will continue their partnership to find therapeutic candidates for cancer for an additional three years.

Pharmaceutical Executive

The 2014 Pharmaceutical Price Regulation Scheme (PPRS), the voluntary agreement to cover pricing of branded medicines supplied to the NHS in the UK, included provisions for member companies to pay back to the Department of Health (DH) if spend went over pre-agreed growth rates.

Pharmaceutical Executive

An illustrious panel of investment professionals spoke optimistically on the orphan disease space in spite of concerns surrounding escalating drug prices in specialty pharmaceuticals.

Pharmaceutical Executive

It’s fall and the 2015 Obamacare Exchange Rx insurance offerings will be presented to patients on November 15th. But at this point, what insights do American Rx brand managers and marketers actually have on the results of the Obamacare Rx experience in 2014?

Pharmaceutical Executive

On September 16, 2014, the Ukrainian and European parliaments ratified the EU–Ukraine Association Agreement (AA), providing for harmonization of many spheres of Ukrainian legislation with EU policy.

Pharmaceutical Executive

The National Institutes of Health (NIH) announced yesterday that it is issuing nearly $32 million in grants for the development of strategies to analyze and leverage biomedical data sets.

Pharmaceutical Executive

After a change in distribution strategy at Genentech, Ascension Health has prohibited sales representatives from the drug maker to solicit physicians at Ascension’s 1900 sites of care around the country.